Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BMS-986458 monotherapy and combination therapy in relapsed/refractory non-Hodgkin lymphoma
CTR20261571Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bms-986458 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events and Incidence of treatment-related safety syndromes. Started Jan 2024; status: active.
02
Drugs
bms-986458
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20261571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261571.